Sugi Predict

Sugi Predict / Targets / AURKA

AURKA

Aurora kinase A · O14965 · AURKA on Sugi Atlas →

338,284 patent compounds predicted against AURKA, 223,460 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL75540 SCHEMBL75540 0.61 14/20
SCHEMBL75557 SCHEMBL75557 0.60 14/20
SCHEMBL75538 SCHEMBL75538 0.58 14/20
SCHEMBL75731 SCHEMBL75731 0.58 14/20
SCHEMBL91083 SCHEMBL91083 0.50 14/20
SCHEMBL91082 SCHEMBL91082 0.74 13/20
SCHEMBL75558 SCHEMBL75558 0.62 13/20
SCHEMBL75628 SCHEMBL75628 0.59 13/20
SCHEMBL91081 SCHEMBL91081 0.61 12/20
SCHEMBL75629 SCHEMBL75629 0.59 12/20
SCHEMBL91085 SCHEMBL91085 0.49 12/20
SCHEMBL75631 SCHEMBL75631 0.76 11/20
SCHEMBL75584 SCHEMBL75584 0.75 11/20
SCHEMBL75646 SCHEMBL75646 0.61 11/20
SCHEMBL62264 SCHEMBL62264 0.55 11/20
Inamrinone Inamrinone (SCHEMBL44012) 1.00 10/20
SCHEMBL84379 SCHEMBL84379 0.67 10/20
SCHEMBL61900 SCHEMBL61900 0.56 9/20
SCHEMBL63742 SCHEMBL63742 0.51 9/20
SCHEMBL82562 SCHEMBL82562 0.39 8/20

Clinical trials — most relevant to AURKA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) PHASE4COMPLETED
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) PHASE2NOT_YET_RECRUITING
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer PHASE2RECRUITING
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer PHASE2RECRUITING
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) PHASE2COMPLETED
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE1/PHASE2COMPLETED
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma PHASE2COMPLETED
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations PHASE2COMPLETED
Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer PHASE1/PHASE2COMPLETED
PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors PHASE1/PHASE2RECRUITING
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas PHASE2COMPLETED
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer PHASE1RECRUITING
Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors PHASE1COMPLETED
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors PHASE1COMPLETED
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas PHASE1COMPLETED
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
MLN8237 in Head and Neck Cancer PHASE1COMPLETED
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma PHASE1COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel PHASE1COMPLETED
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) PHASE1RECRUITING
Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer nanCOMPLETED
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer. nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a AURKA binder may also engage these)

ProteinNameSimilarity
A5GFW1 — 1.000 A5GFW1 →
P59241 — 1.000 P59241 →
P97477 — 0.998 P97477 →
A0A8I3S724 — 0.998 A0A8I3S724 →
Q91819 — 0.997 Q91819 →
Q91820 — 0.996 Q91820 →
Q2TA06 — 0.995 Q2TA06 →
O70126 — 0.994 O70126 →
O59790 — 0.994 O59790 →
D7UQM5 — 0.993 D7UQM5 →
A4IGM9 — 0.993 A4IGM9 →
Q7YRC6 — 0.992 Q7YRC6 →
O08605 — 0.991 O08605 →
DCLK1 Serine/threonine-protein kinase DCLK1 0.991 landscape →
DYRK4 Dual specificity tyrosine-phosphorylation-regulated kinase 4 0.990 landscape →
Q66I46 — 0.990 Q66I46 →
Q6Z8C8 — 0.990 Q6Z8C8 →
O55099 — 0.990 O55099 →
Q96287 — 0.989 Q96287 →
MKNK1 MAP kinase-interacting serine/threonine-protein kinase 1 0.989 landscape →
Q66JF3 — 0.988 Q66JF3 →
Q924X7 — 0.988 Q924X7 →
Q5R667 — 0.988 Q5R667 →
Q9FG74 — 0.988 Q9FG74 →
Q6DGS3 — 0.988 Q6DGS3 →
P11730 — 0.988 P11730 →
AURKB Aurora kinase B 0.988 landscape →
Q9N0X0 — 0.988 Q9N0X0 →
P08413 — 0.987 P08413 →
CDKL4 Cyclin-dependent kinase-like 4 0.987 landscape →